Low-dose radiation therapy (LDRT), combined with dual VEGF and PD-L1 blockade, has been shown to activate intertumoral CD8+ T cells and improve immune responses, helping to overcome ICB resistance in HCC[97]. This evidence concerns the gene CD8A and hepatocellular carcinoma.